Clarity Pharmaceuticals Ltd (CU6.AX)
ASX - ASX Delayed price. Currency in AUD
Add to watchlist
At close: 04:10PM AEDT
| Previous close | 7.12 |
| Open | 7.01 |
| Bid | 6.90 x N/A |
| Ask | 6.98 x N/A |
| Day's range | 6.76 - 7.14 |
| 52-week range | 0.98 - 8.98 |
| Volume | |
| Avg. volume | 2,044,387 |
| Market cap | 2.228B |
| Beta (5Y monthly) | 1.58 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.16 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.30 |
Simply Wall St.Market Sentiment Around Loss-Making Clarity Pharmaceuticals Ltd (ASX:CU6)
Clarity Pharmaceuticals Ltd ( ASX:CU6 ) is possibly approaching a major achievement in its business, so we would like...
PR NewswireSECuRE trial advances: No dose limiting toxicities and strong preliminary efficacy data in first multi-dose cohort
Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce an update on the safety review of the first 3 participants enrolled in cohort 4 of the SECuRE trial who received 2 doses of 67Cu-SAR-bisPSMA. Cohort 4 is the final cohort in the dose escalation phase of the study, with participants receiving a minimum of 2 and a m
- Simply Wall St.
Here's Why We're Not Too Worried About Clarity Pharmaceuticals' (ASX:CU6) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Clarity...
© 2024 Yahoo. All rights reserved.